PO.MCB08.05 · 分子与细胞生物学

未经治疗乳腺癌的综合多组学图谱揭示驱动免疫热型和冷型表型的共存肿瘤-免疫生态系统

A comprehensive multiomics atlas of treatment-naïve breast cancer uncovers co-occurring tumor-immune ecosystems driving immune hot and cold phenotypes

编号 7282 展板 22 时间 4/22 09:00–12:00 区域 Section 21 主讲 Hani Jieun Kim, PhD
分会场 Genomic Approaches to Define Tumor Biology and Clinical Stratification
该海报暂无可下载的资料 AACR 官方页面

作者与单位 Authors & Affiliations

Hani Jieun Kim1, Beata Kiedik1, Kate Harvey1, Sehrish Kanwal2, James Douglas1, John Reeves1, Alexander Lobanov3, Daniel L. Roden1, Sophie Van Der Leij1, Mun N. Hui4, Aziz Al’Khafaji5, Elgene Lim1, Sean M. Grimmond2, Joakim Lundeberg6, Charles M. Perou3, Alexander Swarbrick1

1Garvan Institute of Medical Research, Darlinghurst, Australia,2University of Melbourne, Victoria, Australia,3UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC,4Chris O’Brien Lifehouse, Camperdown, Australia,5Broad Institute of MIT and Harvard, Cambridge, MA,6Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden

摘要 Abstract

中文摘要
乳腺癌是一种在临床和遗传学上高度异质的疾病。尽管单细胞研究推进了我们对该疾病潜在生物学多样性的理解,但以往研究的一个主要局限在于它们未能捕获乳腺癌亚型的广泛谱系,且缺乏解析亚型特异性差异的统计效能。为弥补这一空白,我们生成了一个综合的乳腺癌单细胞图谱,旨在稳健地表征所有主要临床亚型的转录组和基因组异质性。 聚焦于未经治疗的组织以捕获治疗干预前的疾病生物学,我们分析了近200例患者样本,生成了一个包含scRNA-seq、全转录组测序(WTS)、全基因组测序(WGS)以及临床病理数据(如年龄、组织学分级和类型、ER/PR/HER2检测、间质肿瘤浸润淋巴细胞(sTIL)和PD-L1状态)的综合多组学图谱。 为量化肿瘤间和肿瘤内异质性,我们开发了一个乳腺癌原型分析框架,将恶性上皮细胞沿着捕获癌症内在特性的轴进行定位。原型分析成功解析了具有生物学意义的梯度,并系统地量化了转录组异质性。我们的结果表明,管腔型癌症——尤其是Luminal B——表现出最大程度的肿瘤内和肿瘤间多样性。我们定义了促成这种变异性的关键基因程序,并在管腔型癌症中鉴定了免疫程序。使用sTIL状态作为免疫原性的度量,我们鉴定出一个被低估的、表现出高免疫浸润的管腔型肿瘤亚群——这挑战了管腔型癌症一律为"免疫冷型"的主流观点。利用我们的单细胞数据,我们进行了整合分析,以揭示与免疫热型和免疫冷型表型相关的不同共存肿瘤-免疫生态系统。这些观察结果通过我们配对的多模态WGS、WTS和空间转录组数据得到进一步验证。 我们涵盖所有主要临床亚型的单细胞多组学乳腺癌图谱为剖析乳腺癌的多层次异质性提供了一个高分辨率框架。通过最大化患者代表性并整合丰富的临床和基因组元数据,这一资源能够稳健地鉴定亚型特异性生物学,并揭示管腔型乳腺癌内部显著的多样性,包括一个具有免疫热型特征的可观亚群。正在进行的工作将利用这一图谱和我们深度整理的元数据(包括生存结局),以精细化乳腺癌分层并鉴定具有临床可操作性的肿瘤生态系统。
查看英文原文 English abstract
Breast cancer is a clinically and genetically heterogeneous disease. Whilst single-cell studies have advanced our understanding of the underlying biological diversity of this disease, a major limitation in previous studies is that they fail to capture the broad spectrum of breast cancer subtypes and lack the statistical power to resolve subtype-specific differences. To address this gap, we generated a comprehensive breast cancer single-cell atlas designed to robustly characterise transcriptomic and genomic heterogeneity across all major clinical subtypes. Focusing on treatment-naïve tissues to capture disease biology prior to therapeutic intervention, we profiled nearly 200 patient samples to generate a comprehensive multiomics atlas of scRNA-seq, whole transcriptome sequencing (WTS), whole genome sequencing (WGS), and clinicopathological data, such as age, histological grade and type, ER/PR/HER2 measurements, and stromal tumour-infiltrating lymphocyte (sTIL) and PD-L1 status. To quantify inter- and intra-tumoral heterogeneity, we developed a framework of breast cancer archetyping that positions malignant epithelial cells along axes capturing the cancer intrinsic properties. Archetyping successfully resolves biologically meaningful gradients and systematically quantifies transcriptomic heterogeneity. Our results show that luminal cancers-particularly Luminal B-exhibit the largest degree of intra- and inter-tumoural diversity. We define the key gene programs that contribute to this variability and identify immune programs among luminal cancers. Using sTIL status as a measure of immunogenicity, we identified an underappreciated subset of luminal tumours exhibiting high immune infiltration-challenging the prevailing view that luminal cancers are uniformly “immune cold.” Leveraging our single-cell data, we performed integrative analysis to uncover the distinct co-occurring tumour-immune ecosystems associated with immune-hot versus immune-cold phenotypes. These observations were further validated using our matched multimodal WGS, WTS, and spatial transcriptomics data. Our single-cell multiomics breast cancer atlas spanning all major clinical subtypes provides a high-resolution framework for dissecting the multilayered heterogeneity of breast cancer. By maximizing patient representation and integrating rich clinical and genomic metadata, this resource enables robust identification of subtype-specific biology and reveals striking diversity within luminal breast cancers, including a substantial subset with immune-hot characteristics. Ongoing work will leverage this atlas and our deeply curated metadata, including survival outcomes, to refine breast cancer stratification and identify clinically actionable tumour ecosystems.
利益披露 Disclosure
H. Kim, None.. B. Kiedik, None.. K. Harvey, None.. S. Kanwal, None.. J. Douglas, None.. J. Reeves, None.. D. L. Roden, None.. S. Van Der Leij, None.. M. N. Hui, None.. A. Al’Khafaji, None.. E. Lim, None.. S. M. Grimmond, None.. C. M. Perou, None.

← 返回 AACR 2026 检索